blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2961409

EP2961409 - INHIBITORS OF CDK8/19 FOR USE IN TREATING ESTROGEN RECEPTOR POSITIVE BREAST CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.01.2017
Database last updated on 31.08.2024
Most recent event   Tooltip27.01.2017Application deemed to be withdrawnpublished on 01.03.2017  [2017/09]
Applicant(s)For all designated states
Senex Biotechnology, Inc.
715 Sumpter Street
Coker Life Science Building Room 513
Columbia, SC 29208 / US
[2016/01]
Inventor(s)01 / BROUDE, Eugenia
225 Porth Circle
Lexington, SC 29072 / US
02 / RONINSON, Igor, B
225 Porth Circle
Lexington, SC 29072 / US
 [2016/01]
Representative(s)Hiebl, Inge Elisabeth
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[2016/01]
Application number, filing date14713958.826.02.2014
[2016/01]
WO2014US18678
Priority number, dateUS201361769435P26.02.2013         Original published format: US 201361769435 P
[2016/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014134169
Date:04.09.2014
Language:EN
[2014/36]
Type: A1 Application with search report 
No.:EP2961409
Date:06.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 04.09.2014 takes the place of the publication of the European patent application.
[2016/01]
Search report(s)International search report - published on:EP04.09.2014
ClassificationIPC:A61K31/517, A61K31/00, A61K45/06, A61P35/00
[2016/01]
CPC:
A61K31/517 (EP,US); A61K31/00 (EP,US); A61K31/5377 (EP,US);
A61K31/565 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP)
C-Set:
A61K31/517, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/01]
TitleGerman:INHIBITOREN VON CDK8/19 ZUR VERWENDUNG BEI DER BEHANDLUNG VON ÖSTROGENREZEPTORPOSITIVEM BRUSTKREBS[2016/01]
English:INHIBITORS OF CDK8/19 FOR USE IN TREATING ESTROGEN RECEPTOR POSITIVE BREAST CANCER[2016/01]
French:INHIBITEURS DE CDK8/19 POUR UTILISATION DANS LE TRAITEMENT DU CANCER DU SEIN À RÉCEPTEURS D' STROGÈNE POSITIFS[2016/01]
Entry into regional phase25.09.2015National basic fee paid 
25.09.2015Designation fee(s) paid 
25.09.2015Examination fee paid 
Examination procedure25.09.2015Examination requested  [2016/01]
01.09.2016Application deemed to be withdrawn, date of legal effect  [2017/09]
06.10.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2017/09]
Fees paidPenalty fee
Additional fee for renewal fee
29.02.201603   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]US2010069383  (ANDERSON MARK B [US], et al) [I] 1,10-15 * page 6, paragraphs [0057]-[0060] * * page 58, paragraph [1346] * * page 59, paragraph [1351] * * examples 26, 177, 179, 262, 265 *;
 [I]WO2011011522  (HARVARD COLLEGE [US], et al) [I] 1,10-15 * page 42, lines 27-29 * * page 43, line 23 - page 44, line 4 * * claims 39, 41-43, 51, 53-56 * * figure 14 *;
 [A]US2012071477  (PORTER DONALD C [US], et al) [A] 1-18 * figures 1, 2, 6, 7 * * page 3, paragraph [0027] * * page 4, paragraphs [0045]-[0048] * * page 5, paragraph [0051] * * page 6, paragraph [0055] * * page 7, paragraph [0065] * * pages 7-8, paragraph [0070] * * examples 4, 7 *;
 [IP]WO2013116786  (SENEX BIOTECHNOLOGY INC [US]) [IP] 1-18 * page 3, paragraphs 2, 4 * * page 5, paragraph 3 * * page 6, paragraph 9 * * page 7, paragraphs 2-3 * * page 8, paragraph 4 - page 9, paragraph 1 * * page 13, paragraph 6 * * examples 9, 11-14 * * claims 1-30 *;
 [ID]  - D. C. PORTER ET AL, "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120821), vol. 109, no. 34, doi:10.1073/pnas.1206906109, ISSN 0027-8424, pages 13799 - 13804, XP055056523 [ID] 1-18 * abstract * * page 13799, column 2, paragraph 2 * * page 13800, column 1, paragraph 1 * * figure 1 * * page 13802, column 2, paragraph 5 - page 13803, column 2, paragraph 1 * * figure 4 * * page 13804, column 1, paragraph l - column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1073/pnas.1206906109
 [I]  - Steven Powell, "A new approach to improving cancer chemotherapy", University of South Carolina - News, (20120806), page 1, URL: http://www.sc.edu/news/newsarticle.php?nid=4315#.U3nIglPsx8E, (20140519), XP055118617 [I] 1-18 * page 1, paragraphs 2, 9-10 *
 [I]  - ALAFEEFY AHMED M ET AL, "Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, TAYLOR, READING, GB, (20120801), vol. 27, no. 4, doi:10.3109/14756366.2011.601302, ISSN 1475-6366, pages 541 - 545, XP008169336 [I] 1,10-15 * abstract * * figure scheme 1; compounds 4, 5, 12-15 * * page 543, column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.3109/14756366.2011.601302
 [I]  - ESTHER MORENO ET AL, "Sulfur and selenium derivatives of quinazoline and pyrido[2,3-]pyrimidine: Synthesis and study of their potential cytotoxic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 47, doi:10.1016/J.EJMECH.2011.10.056, ISSN 0223-5234, (20111028), pages 283 - 298, (20111106), XP028442406 [I] 1,10-15 * abstract * * figure 2 * * figure scheme 1; compounds 2e-2j, 2l-2o * * figure scheme 3; compounds 7a-7i * * page 287, column 2, paragraph 3 * * table 1 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2011.10.056
 [A]  - MCDONNELL D P ET AL, "The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 10, no. 6, doi:10.1016/J.COPH.2010.09.007, ISSN 1471-4892, (20101201), pages 620 - 628, (20101111), XP027491049 [A] 5-9 * abstract * * page 625, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.coph.2010.09.007
 [XPI]  - LI XIAO-YU ET AL, "siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breastcancer cells", vol. 7, no. 1, ISSN 1936-2625, (20140101), pages 92 - 100, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, E-CENTURY PUBLISHING CORPORATION, US, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885463/, (20131215), XP008169367 [XP] 1 * abstract * * page 93, column 1, paragraphs 2, 5 * * figures 2-4 * * page 96, column 1, paragraph 1 - column 2, paragraph 1 * * page 98, column 1, paragraph 1 * * page 98, column 2, paragraph 2 - page 99, column 1, paragraph 2 * [I] 2-18
by applicant   - BELAKAVADI,M.; FONDELL,J.D., "Cyclin-dependent kinase 8 positively cooperates with Mediator to promote thyroid hormone receptor-dependent transcriptional activation", MOL. CELL BIOL., (2010), vol. 30, pages 2437 - 2448
    - CATANIA,C.; ASCIONE,G.; ADAMOLI,L.; DE,P.T.; MEDICI,M.; FRANCESCHELLI,L.; VERRI,E.; MAGNI,E.; SANNA,G.; TORRISI,R., "Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre", BREAST CANCER RES. TREAT., (2007), vol. 106, doi:doi:10.1007/s10549-006-9481-8, pages 97 - 103, XP019524467

DOI:   http://dx.doi.org/10.1007/s10549-006-9481-8
    - FIRESTEIN,R.; BASS,A.J.; KIM,S.Y.; DUNN,I.F.; SILVER,S.J.; GUNEY,I.; FREED,E.; LIGON,A.H.; VENA,N.; OGINO,S., "CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity", NATURE, (2008), vol. 455, doi:doi:10.1038/nature07179, pages 547 - 551, XP055124701

DOI:   http://dx.doi.org/10.1038/nature07179
    - FIRESTEIN,R.; HAHN,W.C., "Revving the Throttle on an oncogene: CDK8 takes the driver seat", CANCER RES, (2009), vol. 69, pages 7899 - 7901
    - FIRESTEIN,R.; SHIMA,K.; NOSHO,K.; IRAHARA,N.; BABA,Y.; BOJARSKI,E.; GIOVANNUCCI,E.L.; HAHN,W.C.; FUCHS,C.S.; OGINO,S., "CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival", INT. J. CANCER, (2010), vol. 126, pages 2863 - 2873
    - GALBRAITH,M.D.; DONNER,A.J.; ESPINOSA,J.M., "CDK8: a positive regulator of transcription", TRANSCRIPTION, (2010), vol. 1, pages 4 - 12
    - KAPOOR,A.; GOLDBERG,M.S.; CUMBERLAND,L.K.; RATNAKUMAR,K.; SEGURA,M.F.; EMANUEL,P.O.; MENENDEZ,S.; VARDABASSO,C.; LEROY,G.; VIDAL,C, "The histone variant macroH2A suppresses melanoma progression through regulation ofCDK8", NATURE, (2010), vol. 468, pages 1105 - 1109
    - MCDONNELL,D.P.; WARDELL,S.E., "The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer", CURR. OPIN. PHARMACOL., (2010), vol. 10, doi:doi:10.1016/j.coph.2010.09.007, pages 620 - 628, XP027491049

DOI:   http://dx.doi.org/10.1016/j.coph.2010.09.007
    - MULLER,A.; HOMEY,B.; SOTO,H.; GE,N.; CATRON,D.; BUCHANAN,M.E.; MCCLANAHAN,T.; MURPHY,E.; YUAN,W.; WAGNER,S.N., "Involvement of chemokine receptors in breast cancer metastasis", NATURE, (2001), vol. 410, doi:doi:10.1038/35065016, pages 50 - 56, XP002292390

DOI:   http://dx.doi.org/10.1038/35065016
    - PORTER,D.C.; FARMAKI,E.; ALTILIA,S.; SCHOOLS,G.P.; WEST,D.K.; CHEN,M.; CHANG,B.D.; PUZYREV,A.T.; LIM,C.U.; ROKOW-KITTELL,R., "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor- promoting paracrine activities", PROC. NATL. ACAD. SCI. U. S. A, (2012), vol. 109, doi:doi:10.1073/pnas.1206906109, pages 13799 - 13804, XP055056523

DOI:   http://dx.doi.org/10.1073/pnas.1206906109
    - RAE,J.M.; JOHNSON,M.D.; SCHEYS,J.O.; CORDERO,K.E.; LARIOS,J.M.; LIPPMAN,M.E., "GREB 1 is a critical regulator of hormone dependent breast cancer growth", BREAST CANCER RES. TREAT., (2005), vol. 92, pages 141 - 149, XP019274841
    - RHODES,L.V.; SHORT,S.P.; NEEL,N.F.; SALVO,V.A.; ZHU,Y.; ELLIOTT,S.; WEI,Y.; YU,D.; SUN,M.; MUIR,S.E., "Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer", CANCER RES., (2011), vol. 71, pages 603 - 613
    - SAUVE,K.; LEPAGE,J.; SANCHEZ,M.; HEVEKER,N.; TREMBLAY,A., "Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway", CANCER RES., (2009), vol. 69, pages 5793 - 5800
    - SIKORA,M.J.; STRUMBA,V.; LIPPMAN,M.E.; JOHNSON,M.D.; RAE,J.M., "Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation", BREAST CANCER RES. TREAT., (2012), vol. 134, doi:doi:10.1007/s10549-012-2032-6, pages 1027 - 1039, XP035093059

DOI:   http://dx.doi.org/10.1007/s10549-012-2032-6
    - SWEENEY,E.E.; MCDANIEL,R.E.; MAXIMOV,P.Y.; FAN,P.; JORDAN,V.C., "Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations", HORM. MOL. BIOL. CLIN. INVESTIG., (2012), vol. 9, pages 143 - 163
    - WANG YC; MORRISON G; GILLIHAN R; GUO J; WARD RM; FU X; BOTERO MF; HEALY NA; HILSENBECK SG; PHILLIPS GL, "Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation", BREAST CANCER RESEARCH, (2011), vol. 13, doi:doi:10.1186/bcr3067, page R121, XP021119741

DOI:   http://dx.doi.org/10.1186/bcr3067
    - WESTERLING,T.; KUULUVAINEN,E.; MAKELA,T.P., "Cdk8 is essential for preimplantation mouse development", MOL. CELL BIOL., (2007), vol. 27, pages 6177 - 6182
    - WILSON,T.R.; FRIDLYAND,J.; YAN,Y.; PENUEL,E.; BURTON,L.; CHAN,E.; PENG,J.; LIN,E.; WANG,Y.; SOSMAN,J., "Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors", NATURE, (2012), vol. 487, pages 505 - 509
    - XU,W.; JI,J.Y., "Dysregulation of CDK8 and Cyclin C in tumorigenesis", J. GENET. GENOMICS, (2011), vol. 38, doi:doi:10.1016/j.jgg.2011.09.002, pages 439 - 452, XP028327936

DOI:   http://dx.doi.org/10.1016/j.jgg.2011.09.002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.